Finding NMO: The Evolving Diagnostic Criteria of Neuromyelitis Optica

Download item | Update item information
Title Finding NMO: The Evolving Diagnostic Criteria of Neuromyelitis Optica
Creator Jeffrey L. Bennett, MD, Gertrude Gilden Professor of Neurology and Ophthalmology, University of Colorado
Affiliation Departments of Neurology, Ophthalmology, and Program in Neuroscience, University of Colorado Denver, Aurora, Colorado
Subject Adult; Aged; Disease Management; Eye Movements; Female; Follow-Up Studies; Humans; Isaacs Syndrome; Middle Aged; Oculomotor Muscles; Ophthalmologic Surgical Procedures; Retrospective Studies; Strabismus; Treatment Outcome
Abstract There is currently no prognostic test to determine the risk of developing generalized myasthenia gravis (GMG) risk in patients who first present with ocular disease. Most studies that report risk factors are flawed by the inclusion of patients on immunosuppression, which is likely to reduce the risk.; ; To create a prognostic score to predict the risk of GMG.; ; Multicenter retrospective cohort of patients with ocular myasthenia gravis for minimum 3 months, untreated with immunosuppression for minimum 2 years or until GMG onset.; ; One hundred one (57 female) patients were included, with median follow-up of 8.4 years (2-42) from disease onset. Thirty-one developed GMG at median of 1.31 years (3.5 months-20.2 years); 19 occurred within 2 years. Univariable logistic regression analysis produced 3 significant predictors (P < 0.10), adjusted odds ratios in a multivariable logistic model (χ P = 0.01) with multiple imputations for missing data: seropositivity, 5.64 (95% CI, 1.45-21.97); presence of 1 or more comorbidities including autoimmune disorders, 6.49 (95% CI, 0.78-53.90); thymic hyperplasia, 5.41 (95% CI, 0.39-75.43). Prognostic score was derived from the coefficients of the logistic model: sum of the points (1 point for the presence of each of the above predictive factors), classified "low risk" if ≤1 and "high risk" if ≥2. Predicted probabilities were 0.07 (SD, 0.03) for low risk and 0.39 (SD, 0.09) for high risk. Negative predictive value was 91% (95% CI, 79-98), positive predictive value was 38% (95% CI, 23-54), sensitivity was 79% (95% CI, 54-94), specificity was 63% (95% CI, 50-74), area under receiver operating characteristic curve was 0.74 (95% CI, 0.64-0.85).; ; In this preliminary study, we have shown by proof of principle that it is possible to stratify risk of GMG: an approach that may allow us to better counsel patients at diagnosis, complement decision-making, and move us toward addressing the question of modifying GMG risk in high-risk patients. Furthermore, the effect of comorbidities is novel and demands further elucidation.
OCR Text Show
Publisher Lippincott, Williams & Wilkins
Date 2016-09
Type Text
Source Journal of Neuro-Ophthalmology, September 2016, Volume 36, Issue 3
Relation NOVEL: Journal of Neuro-Ophthalmology Collection
Rights Management © North American Neuro-Ophthalmology Society
Publication Type Journal Article
ARK ark:/87278/s6pg5m54
Setname ehsl_novel_jno
Date Created 2017-09-14
Date Modified 2017-09-14
ID 1276517
Reference URL
Back to Search Results